IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

New Routes of Insulin for Diabetes Treatment

Mangesh Shalik Holgare[1], Nitin B. Kohale[2], Suraj B. Rathod[3]
Students[1], Principal[2] and Assistant Professor[3]
Vardhman College of Pharmacy, Koli, Karanja (Lad), Washim, Maharashtra, India
mangesh12holgare@gmail.com

Abstract: *Diabetes is a chronic condition marked by insufficient insulin production and the subsequent hyperglycemia. Optimal diabetes control has an impact on both microvascular and macrovascular disease, which are both diabetic consequences. Subcutaneous insulin injections or continuous infusions are frequently used by people with diabetes to manage their blood sugar levels. Given that insulin injection therapy is difficult for many patients, novel routes of insulin administration are of interest in the diabetes sector. Inhalational insulin administration will be covered in this review. The effectiveness of inhaled insulin in comparison to subcutaneous insulin in the various populations with diabetes iscovered, as well as its safety. Additionally, the experience and challenges associated with the creation and promotion of insulin for inhalation are reviewed.*

Keywords: Glycemic Control, Hemoglobin A1c, Inhalation, Insulin, Kind 1 Diabetes, Kind 2 Diabetes

I. INTRODUCTION

A group of disorders known as diabetes are characterised by high blood sugar levels in the face of insufficient insulin synthesis or activity. Approximately 23.6 million Americans (8% of the population) are afflicted by the illness, and a full third of those people don't even know they have it. 1 Type 1 (T1DM) and type 2 diabetes are the two main subtypes of the disease (T2DM). T1DM patients require subcutaneous delivery of insulin via injection or continuous infusion in order to survive. T2DMpatients may temporarily regulate their condition with dietary changes or oral medications. However, insulin will be necessary for people who fail to achieve appropriate illness control if they use these treatments. In the therapy of diabetes, inhaled insulin delivery is a potential substitute for subcutaneous insulin.

1.1 Rationale for Intensified Diabetes Care

Associations among hyperglycemia and the long-time period headaches of diabetes had been verified each in animal fashions and human research. Elevated glucose stages result in tremendous vascular endothelial mobileular dysfunction, contributing to morbidities related to the ailment.2 Individuals with diabetes are at chance for each microvascular ailment along with nephropathy, retinopathy, and neuropathy and macrovascular ailment along with each deadly and nonfatal myocardial infarction and stroke. Epidemiologic research have verified a correlation among diabetes and cardiovascular ailment. The analysis of T2DM will increase the chance of coronary coronary heart ailment via way of means of a issue of 2- to 4-fold,3 whilst people with T1DM have approximately a 10-fold growth in cardiovascular ailment as compared to age-matched people with out diabetes.4,five Large potential trials, along with the Diabetes Control and Complications Trial (DCCT, T1DM)6 and the UK Prospective Diabetes Study (UKPDS, T2DM),7 have verified that enhancing metabolic control, as measured via way of means of suggest glycosylated hemoglobin (HbA1c), decreases the chance of microvascular headaches. Declines in HbA1c correlate with discounts in each the improvement and development of diabetic retinopathy, nephropathy, and neuropathy, indicating that addressing hyperglycemia is applicable even in people with mounted headaches. These huge trials did now no longer display declines in macrovascular ailment with advanced blood sugar control. However, withinside the Epidemiology of Diabetes Interventions and Complications Trial (EDIC), a follow-up of the DCCT, sufferers who had acquired intensified remedy for a duration of 6.five years had a 42 crease withinside the chance of a primary cardiovascular occasion as compared to the conventionally dealt with group.6 More latest research have known as into query the intention of striving for near-regular glycemic control (HbA1c < 6> While extensive remedy is diagnosed as a way to enhance long-time period consequences for sufferers with diabetes, fewer than 40% of sufferers gain the glycemic objectives set forth through the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

Barriers to accomplishing those dreams are multi-factorial and encompass failure of sufferers to just accept intensified healing procedures and lack of ability of present day regimens to imitate physiologic insulin delivery. Intensive remedy in T1DM includes a couple of each day subcutaneous injections of insulin (three to five according to day) generally with long-appearing insulin as basal insulin and short-appearing insulin administered simply previous to meals. Alternatively, non-stop subcutaneous insulin infusion (CSII) pumps may be used. For people with T2DM, preliminary control consists of life-style interventions along with food plan and exercise. However, maximum sufferers will subsequently require oral cures that stimulate pancreatic β-mobileular insulin secretion (secretagogues) or enhance insulin sensitivity (biguanides or thiazolidinediones). If glycemic dreams aren't met, insulin remedy should be initiated. For sufferers with diabetes, both intensifying (T1DM) or adding (T2DM) insulin remedy may be challenging. Patients frequently withstand transitioning to insulin injections out of worry and situation approximately the ability units had to correlate carbohydrate consumption with insulin administration.8 Because of those concerns, intensification of insulin remedy to enhance metabolic manage is frequently delayed, and adherence to injection regimens can be suboptimal. Secretion of insulin in reaction to carbohydrate consumption is tightly regulated.9 Insulin is launched into the portal venous machine to exert results on the liver initially, suppressing glycogenolysis and gluconeogenisis earlier than appearing peripherally to stimulate glucose uptake and inhibit lipolyis.10 Current techniques of subcutaneous insulin management do now no longer mimic this first-byskip impact of insulin on hepatic glucose control. Thus, specifically for fasting/basal glucose control, subcutaneous remedy fails to repair intra-portal insulin concentrations ensuing in irrelevant hepatic glucose output. Attempts to deal with this healing problem with the aid of using growing doses of basal insulin might also additionally area the affected person at threat for hypoglycemia, specifically withinside the fasting state. While to be had insulin analogs offer progressed insurance of meal-time glucose excursions, timing of insulin management and cautious interest to matching carbohydrate ingestion with insulin dose is paramount to restriction post-prandial hyperglycemia. Therapies aimed toward addressing those issues consist of oral insulin (intestinal absorption and buccal mucosal absorption), implantable peritoneal insulin pumps, and inhaled insulin. While enteral insulin remedy is confined via way of means of enzymatic degradation, there are ongoing trials to evaluate the feasibility of oral spray insulin withinside the remedy of T1DM as compared to two times day by day insulin injections (www.clinicaltrials.gov identifier NCT00668850).11 A latest have a look at confirmed that as compared to conventional CSII, sufferers the usage of the implantable peritoneal insulin pump had decreased HbA1c with greater time spent withinside the euglyemic variety and much less time withinside the hyperglycemic variety. However, this feature can be confined via way of means of price and does deliver the danger of peritoneal infections and implantation web website online complications.12 Finally, pulmonary transport of insulin, which turned into first examined in 1924,13,14 has been a place of lively research and development. The lung as a vehicle for drug adminstration Pulmonary shipping of medication is used notably withinside the remedy of breathing sicknesses along with asthma, persistent obstructive pulmonary disease (COPD), and cystic fibrosis. Treatment desires for those problems are to supply capsules regionally to have an effect on bronchospasm (β-agonists), inflammation (inhaled steroids), and neighborhood bacterial infection (antibiotics), at the same time as restricting systemic effects. The distal lung affords a huge floor area (one hundred forty five m2) with a thin (0.2 μM) alveolar epithelium taking into consideration absorption of debris into the bloodstream for systemic action.15 Factors which impact the distribution of medication to the distal lung consist of particle length, particle speed, and ventilatory parameters. In order for debris to be deposited withinside the alveolar space, their length must be among 1 and three μM; smaller debris are exhaled and debris >five μM are deposited withinside the higher airlines or swallowed.16 Patient cooperation and suitable ventilator method are crucial to make sure reproducible shipping of drug to the deep lung. Inhalers that permit for launch of the insulin debris on the begin of a deep, gradual inhalation offer the exceptional penetration to the alveolar space.17,18 Rapid shallow inhalations result in massive losses of the drug withinside the oropharynx and higher airlines. Thus, cappotential to carry out suitable respiratory maneuvers performs an crucial position in maximizing the effectiveness of inhaled insulin therapy.

1.2 Development of Inhaled Insulin

Shortly after Banting and Best determined insulin withinside the early 1920s,19 the primary research the usage of inhaled insulin had been performed. In those research, it turned into mentioned that blood glucose reduced in reaction to

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

inhalation of insulin.14,20 In 1987, it turned into validated that nebulized human insulin furnished blood sugar manipulate corresponding to subcutaneous insulin in 6 kids with T1DM.21 However, it turned into diagnosed that the bioavailability of inhaled insulin turned into extensively decrease than that of subcutaneous preparations. Consequently, it turned into now no longer till the improvement of progressed transport gadgets and expertise of particle pharmacology that inhaled insulin have become prepared for medical study.

1.3 Inhaled Insulin Devices

Devices able to handing over particulate insulin to the alveolar area had been evolved and studied in a whole lot of medical protocols. The best tool have to now no longer best supply insulin in a regular style which will acquire finest glycemic control, however additionally have to be handy for patients – each transportable and user-friendly. Over the direction of the remaining 20 years, numerous corporations have labored to increase inhaled insulin structures for affected person use. The structures fluctuate withinside the formula of the inhaled insulin – liquid vs lyophilized powder – and the transport tool with appreciate to size, mechanism of insulin release, and law of insulin administration (mechanical vs electronic). The bioavailability of inhaled insulin for every of the gadgets varies, however is withinside the variety of 10% to 46%, with an awful lot of the drug being misplaced withinside the tool or withinside the oropharynx or higher airways.22Table 1 summarizes the capabilities of inhaled insulin transport structures which have been studied maximum extensively.

1.4 Inhaled Insulin Systems

Exubera® changed into evolved thru a collaboration among Nektar Therapeutics and Pfizer and, in 2006, changed into permitted through the Food and Drug Association (FDA) and the European Medicines Agency (EMEA) for remedy of each T1DM and T2DM. The insulin added through this tool is a dry powder system packaged in blister packets containing 1 mg or three mg of ordinary human insulin. The unit doses are added through a mechanical inhaler and are equal to a few devices and eight devices of subcutaneously added short-performing insulin, respectively. Much of the scientific literature describing the pharmacokinetics, glucodynamics, and protection profiles of inhaled insulin changed into acquired from research the use of Exubera®. However, in October 2007, Pfizer introduced that it'd now not be promoting Exubera® secondary to bad income and acceptance. The AERx insulin diabetes control machine (AERx® iDMS) changed into advanced with the aid of using each Aradigm Corporation and Novo Nordisk. This machine creates an aerosol of insulin droplets from a liquid insulin preparation. The tool has digital controls that manual the consumer to inhale the insulin in a reproducible fashion. In addition, the tool gives the functionality to down load dosing, use frequency, and inhalation styles to resource the prescriber and affected person in tracking adherence and remedy goals. Although the AERx® machine changed into in section III trials, Novo Nordisk elected to stop similarly have a look at with this machine given the enjoy of Pfizer with Exubera®. AIR® insulin gadget, evolved together with Eli Lilly and Co. and Alkermes Inc. makes use of a dry powder insulin with a mechanical inhaler. The inhaled debris are appreciably larger (five to 30 μM), but much less dense than the ones of different systems, and are added successfully to the alveolar space. While this gadget has been via sizable section III testing, Eli Lilly and companions aren't pursuing improvement of this product at present. The Technosphere® device combines a dry powder recombinant human insulin (Mannkind Corp.) with the MedTone® inhaler (Pharmaceutical Discovery Corp.). This device is presently in section III trials and is precise in that the companions have evolved a placebo system for inhalation, taking into consideration layout of double-blind, placebo managed research in sufferers with T2DM.23 Technosphere® compares favorably to everyday insulin administrated subcutaneously in controlling postprandial hyperglycemia, suggesting that this system can also additionally offer stepped forward blood sugar control.24 While there are different inhaled insulin devices/structures which have been developed, an awful lot of the research on this vicinity has been halted. A overview of www.clinicaltrials.gov the usage of inhaled insulin as a key phrase found out seventy five trials, 20 of which have been terminated earlier than projected final touch dates. Only five trials of inhaled insulin are indexed as both actively recruiting or now no longer but recruiting, four of that are investigating Technosphere® insulin.25 Mannkind has filed a brand new drug software with the FDA; it stays to be visible whether or not this software may be approved.26

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

1.5 Pharmacology of Inhaled Insulin

Discussion of the pharmacology of inhaled insulin entails each the have a look at of pharmacokinetics – dimension of serum insulin tiers following management of the drug – and pharmacodynamics – dimension of onset and period of hypoglycemic impact. Most of the inhaled insulin gadgets are designed for use along side carbohydrate consumption, concentrated on manipulate of prandial glucose excursions. The best gadget could carefully mimic β-mobileular secretion of insulin with fast onset of motion accompanied with the aid of using sustained hobby over a length of 2–three hours to govern growing glucose concentrations even as restricting not on time hypoglycemic effects. The majority of research evaluate exceptional inhaled insulin transport structures to everyday insulin administered subcutaneously which has a height impact on glycemia 30–60 mins after management and period of motion as much as 4 hours.

1.6 Pharmacokinetics of Inhaled Insulin

Studies to evaluate serum concentrations of insulin following inhalation were accomplished in wholesome volunteers as nicely people with each T1DM and T2DM. A precis of the pharmokinetic parameters for numerous inhaled insulin gadgets is supplied with the aid of using Patton et al.22 In a contrast of Exubera® and everyday insulin in wholesome nonsmoking males, the entire insulin publicity changed into comparable for inhaled insulin and everyday insulin.27 However, the time to maximal insulin concentration (Cmax) changed into extra speedy for inhaled insulin vs everyday insulin (fifty five min vs 148 min). In an open-label 4manner crossover observe in wholesome volunteers evaluating three distinct Technosphere® inhaled insulin doses and everyday insulin, comparable effects had been found – Cmax changed into 12 to 17 min for Technosphere insulin and 134 min for everyday insulin.28 Studies accomplished with the AERx® gadget in sufferers with T1DM additionally found out there has been a extra speedy upward thrust in serum insulin withinside the inhaled institution vs everyday insulin institution.29 However, the intrasubject variability with appreciate to overall insulin publicity changed into ~26% for the inhaled institution, indicating that constant inhalation strategies should play a great function in diabetes control. Rave et al in comparison Technosphere® insulin to everyday insulin in sixteen sufferers with T2DM.24 Cmax changed into reached earlier (15 min vs one hundred twenty min) and changed into 45% more for inhaled insulin in comparison to everyday insulin. In addition, even as the entire insulin publicity for inhaled insulin changed into corresponding to that of subcutaneous insulin, the publicity time changed into shorter with inhaled insulin, suggesting that the hazard of behind schedule hypoglycemia can be much less with the inhaled insulin formulation.24

1.7 Glucodynamics of Inhaled Insulin

Glucodynamics is measured with the aid of using figuring out the infusion price of glucose vital to keep euglycemia following the management of insulin. This parameter determines the hypoglycemic impact of therapy. In wholesome adult males receiving inhaled insulin, charges of glucose infusion had been better withinside the first hour after dosing than in the ones receiving ordinary insulin with the aid of using injection, correlating with the extra speedy upward thrust in serum insulin tiers.27 This maximal impact on glycemia is similar to short-appearing insulin analogs. Total glucose intake turned into similar for bioequivalent doses of inhaled vs ordinary insulin over the whole clamp period.27 In people with T1DM, the glucose infusion price profile confirmed an early height price with inhaled insulin (AERx®) vs ordinary insulin with a comparable glucose intake.29 Rave et al completed mixed-meal tolerance checks in sixteen people with T2DM and in comparison the cappotential of Technosphere® insulin and ordinary insulin to govern postprandial glucose tiers. Both maximal postprandial glucose tour and general blood glucose region beneathneath the curve had been drastically decrease following use of inhaled insulin on this group, indicating that for comparable insulin exposure, glycemic manipulate turned into advanced with inhaled insulin.24 The speedy onset of movement coupled with the cappotential to exert an impact on glucose tiers for numerous hours after management, makes inhaled insulin a great candidate for manipulate of meal-time glucose tiers. Bioavailability of inhaled insulin is constrained via way of means of numerous elements together with losses of the drug inside the inhalation tool, oropharynx, or higher airways, in addition to ok ventilatory maneuvers to deposit insulin to the decrease airways.22 In research the usage of the AERx® tool in people with T1DM, it changed into anticipated that the device performance on a unit/kilogram foundation changed into 13% as measured via way of means of glucodynamics in comparison to injected everyday

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

insulin.29 This suggests that greater insulin is wanted for inhalation remedy in comparison to injection, a component that may play a function in hazard of long-time period aspect consequences in addition to value of remedy.

1.8 Equivalence Dosing of Inhaled Insulin

Pharmacokinetic and glucodynamic research had been achieved to decide the equivalence of every inhaled insulin formula relative to subcutaneous insulin.30,31 These outcomes are summarized in Table 1. In order for sufferers to get hold of the proper quantity of insulin to cowl carbohydrate ingestion, they need to carry out a sequence of inhalations the usage of the doses to be had for every transport system. For example, a affected person commonly requiring 10 devices of normal insulin ought to inhale both 3 1 mg blisters (nine unit equivalents) or one 1 mg blister and one three mg blister (eleven unit equivalents) of Exubera® to attain a similar insulin dose. A take a look at became achieved in healthful nonsmoking adults to decide whether or not extraordinary dose mixtures of AIR® drugs have been interchangeable.32 The pharmacokinetic and glucodynamic outcomes established that mixtures of various AIR® tablet dose strengths have been equal. Thus, there may be extra flexibility with insulin dosing in addition to much less glycemic variability whilst equal dose strengths are interchanged on this system.

1.9 Use of Inhaled Insulin in Treatment of Diabetes

Several studies have been conducted in patients with T1 and T2DM to evaluate the efficacy of inhaled insulin in controlling diabetes. Inhaled insulin was compared to regular insulin or short-acting insulin analogues in people with type 1 diabetes.

Studies in people with type 2 diabetes have examined the effects of inhaled insulin on diabetes control when combined with oral therapy and compared it with shortacting insulin. Outcome measures include HbA1c, lung function, weight gain, and patient satisfaction.33

Type 1 diabetes

Subcutaneous insulin injections given several times daily (2 to 5) or insulin pump therapy with CSII are the current methods for lowering blood sugar levels in people with T1DM. Patients taking injection therapy typically receive short-acting insulin with meals to cover post-prandial meal excursions in addition to long-acting (basal) insulin 1 or 2 times per day. Multiple daily injectable therapy burdens patients and is a serious obstacle to maximising compliance with diabetes regimens intended to enhance glycemic control. Short-acting insulin analogues could be replaced by inhaled insulin, avoiding up to 4 daily injections. Inhaled insulin administered earlier than food has been in comparison in a randomized managed style to regimens the usage of normal insulin preprandially and both NPH (two times daily) or ultralente (as soon as daily). In research accomplished the usage of Exubera®, inhaled insulin become noninferior with recognize to HbA1c changes, even though 2-hour postprandial and fasting plasma glucose stages had been 35 In a current take a look at suggested with the aid of using Garg et al 385 people with T1DM had been randomized to get hold of both inhaled insulin (AIR®) or normal/lispro insulin earlier than food with glargine serving because the basal insulin.36 After 2 years of take a look at reached a goal HbA1c of < 7>1c. When people with T1DM had been handled itself or to the basal insulin utilized in every take a look at. T1DM have been handled with glargine as basal insulin and randomized to both Technosphere® inhaled insulin or fast performing insulin analog, each corporations had similar decreases in HbA1c at 1 year; however, the inhaled insulin institution had notably decrease fasting plasma glucose and 1 hour postprandial glucose ranges in comparison to the ones on subcutaneous insulin.37 The discrepancies among the research associated with consequences of inhaled insulin on HbA1c can be associated both to the inhaled insulin formula itself or to the basal insulin utilized in every study.

Type 2 diabetes

Individuals with T2DM regularly have complex remedy regimens whilst the addition of insulin is considered. Patients can be taking numerous specific lessons of medication so one can manipulate blood sugars – oral hypoglycemic marketers (sulfonylureas or meglitinides) and insulin sensitizers (biguanides or thiazolidindiones). Rosenstock et al accomplished an ordeal in T2DM sufferers on twin oral agent remedy who persevered to have bad glycemic manipulate (HbA1c > 8%). Patients had been randomized to persevered oral remedy, oral remedy plus Exubera®, or Exubera®

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

alone. HbA1c stepped forward through 1.4% (inhaled) and 1.9% (inhaled plus oral marketers) in comparison to oral marketers alone.38 This shows that a few sufferers can also additionally acquire ok glycemic manipulate on inhaled insulin alone, thereby simplifying their remedy regimen. In addition, people randomized to inhaled insulin plus oral marketers had a extra probability of attaining glycemic objectives in comparison to the ones on oral marketers alone (32% vs 1%).38 As mentioned above, Mannkind Corporation has evolved a placebo primarily based totally tool to be used in medical trials as a comparator to Technosphere® inhaled insulin. This controls for the eye obtained with the aid of using topics inside a look at in addition to the incentive thing ascribed to topics who're randomized to inhaled insulin, in evaluation to subcutaneous insulin, which can bias look at outcomes. Individuals with T2DM suboptimally managed on oral retailers had been randomized In a double-blind style to get hold of both placebo Technosphere® powder or Technosphere® insulin earlier than meals.23 Use of inhaled insulin led to a huge decline in HbA1c in comparison to the ones the use of placebo, considering that HbA1c turned into mildly increased in all topics at baseline (8%, inhaled insulin group; 7.8% placebo group). In a have a look at of sufferers with T2DM on insulin remedy, topics obtained both pre-meal Exubera® plus ultralente (subcutaneous) or two times each day injections of ordinary and NPH insulin.39 There became no distinction withinside the discount in HbA1c among the corporations, despite the fact that the ones randomized to inhaled insulin had been much more likely to obtain HbA1c < 7>® premeal inhaled insulin became as compared to premeal subcutaneous ordinary insulin, each in aggregate with bedtime NPH insulin.40 After 12 weeks of remedy, there has been no distinction in HbA1c among the 2 corporations, and each corporations skilled a comparable decline in HbA1c from baseline (−0.69% vs −0.77%; inhaled vs subcutaneous). A similarly have a look at in people with poorly managed T2DM receiving oral remedy plus basal glargine validated that the addition of AIR® inhaled insulin to once-each day glargine led to a extra development in HbA1c (−0.97% vs −0.62%; inhaled + glargine vs glargine), even if glargine dose became titrated to optimize glycemic manage.41 Individuals with T2DM to begin with randomized to both inhaled or subcutaneous insulin in a 12-week evidence of idea have a look at had been presented the choice of persevering with inhaled insulin for 1 year.30 In people who elected to hold inhaled insulin, the lower in HbA1c (−0.78%) became sustained all through the extension trial, indicating that the healing outcomes on glycemic manage are durable.42 It need to be mentioned that, consequently far, no scientific trial has validated that inhaled insulin is advanced to subcutaneous insulin for the intention of diabetes care – advanced glycemic manage.

1.10 Special Populations Smoking and Inhaled Insulin

It is expected that 20% to 25% of people with diabetes are tobacco people who smoke.43 Smoking induces each acute and continual outcomes at the pulmonary system, inclusive of vasoconstriction, modifications in permeability, and transforming of the bronchioalveolar lining. Therefore, efforts were made to deal with the outcomes that smoking has at the pharmacokinetics of inhaled insulin. Following management of inhaled insulin, nondiabetic continual people who smoke have a better Cmax, more absorption of insulin (AUC0–360), and shorter time to Cmax nonsmokers.44,45 These records recommend that folks who smoke might be at better hazard for hypoglycemia while handled with inhaled insulin. Becker et al tested the outcomes of smoking cessation on pharmacokinetics of inhaled insulin.46 Within 1 week of smoking cessation, the Cmax and AUC0–360 after inhaled insulin had reduced extensively and approached that of nonsmokers. Resumption of smoking reversed the outcomes of smoking cessation, with each insulin publicity and glucose usage increasing. However, tobacco use is likewise related to insulin-resistance,47 and Wise et al tested that despite the fact that nondiabetic people who smoke had a more publicity to insulin following inhalation in comparison to nonsmokers, they did now no longer have expanded glucose usage as measured through glucose infusion rates.44 Therefore, in particular withinside the T2DM population, the boom in alveolar permeability that results in expanded insulin absorption following inhalation can be counteracted through the outcomes of insulin resistance mediated each through the ailment country and smoking. In evaluation to continual smoking, those who are uncovered to passive smoking have a exceptional reaction to inhaled insulin. In wholesome nonsmokers, publicity to cigarette smoke for two hours previous to insulin inhalation led to extensively decrease insulin bioavailability and pharmacokinetic parameters.48 This is just like the impact of acute cigarette smoking simply previous to insulin inhalation through smokers, in which the AUC0–360 isn't always increased.45 Thus, smoking, whether or not acute or continual, passive or primary, affects the pharmacokinetics of inhaled insulin, setting sufferers at chance for fluctuations in blood sugars with ensuing suboptimal metabolic control. When inhaled insulin become at the marketplace, it become now no longer

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

authorized for people who smoke or for individuals who had smoked in the preceding 6 months. Given the reality that Pfizer and Nektar Pharmaceuticals introduced an growth in lung most cancers instances in former people who smoke concerned in medical trials of Exubera®, it's miles not going that any inhaled insulin that involves marketplace withinside the destiny can be authorized for both people who smoke or preceding people who smoke.49

1.11 Respiratory Disease and Inhaled Insulin

Because each acute and continual respiration sicknesses have the capability to regulate the pharmacodynamic results of inhaled insulin, it's miles essential to recognize how infection and pulmonary pathology affect inhaled insulin action. Acute respiration ailments are a not unusualplace prevalence and are observed through cough, mucous production, and irritation of the pulmonary tree. In nondiabetic adults, there has been no distinction withinside the pharmacokinetics or glucose reaction to inhaled insulin both for the duration of the intense or recuperation segment of an top respiration tract infection.50 In addition, pulmonary feature tests (PFTs) following management of inhaled insulin have been unchanged withinside the identical topics. These observations advocate inhaled insulin is effective even withinside the medical placing of acute top respiration infection. Comparable research have now no longer been finished in topics convalescing from decrease respiration tract infections inclusive of pneumonia. Asthma is a continual disorder characterised through irritation and airway hyperreactivity with durations of exacerbation and quiescence. In order for inhaled insulin to be encouraged on this population, it should now no longer cause bronchospasm, and it should be offer most excellent blood sugar manage in the course of acute bronchial allergies exacerbations. In a examine of non-diabetic topics with moderate to slight bronchial allergies, it become proven that in comparison to healthful topics, the general publicity to insulin (AUC) become 34% to 41% less.51 The glucodynamic outcomes of inhaled insulin have been similar among healthful and topics with moderate bronchial allergies, even as the cappotential of inhaled insulin to decrease serum glucose become reduced in topics with slight bronchial allergies. This impact become ameliorated through pretreating topics with a long-appearing β-agonist to relieve airway narrowing. There have been no acute bronchial allergies exacerbations because of insulin inhalation.51 The occurrence of diabetes in sufferers with COPD is as excessive as 12%.52 This disorder is categorised as being each restrictive (emphysema) and obstructive (continual bronchitis) in its consequences on pulmonary feature. These headaches might also additionally restrict the capacity of people to apply the inhalation gadgets accurately or might also additionally limition the floor region to be had for insulin absorption throughout the alveolar membrane. Rave et al completed a randomized cross-over take a look at evaluating the responses to inhaled vs subcutaneous short-performing insulin in each wholesome controls (nonsmokers) and people with COPD who had now no longer smoked for longer than 6 months.53 They verified that even as inhaled insulin became properly tolerated in people with continual lung disorder, serum ranges of immunoreactive insulin following inhaled insulin management have been decrease in people with COPD, specifically in people with continual bronchitis as compared to manipulate subjects. The insulin impact in sufferers with COPD became 60% to 65% of the manage subjects. Thus, for people with COPD, accelerated doses of inhaled insulin can be vital to attain the equal diploma of metabolic manage. There have been no acute consequences on pulmonary feature in reaction to insulin inhalation.53

1.12 Age and Inhaled Insulin

Both lung volumes and diffusion capability alternate as a characteristic of age.54 These adjustments can modulate each transport of inhaled insulin to the distal airways, in addition to absorption of the insulin throughout the alveolar epithelium. Henry et al proven that during people with T2DM, growing age (>sixty five years) impacted the cappotential of inhaled insulin to decrease glucose ranges in comparison to a more youthful population (age 18 to forty five years) whilst Cmax and AUC0–360 have been now no longer one of a kind among the 2 groups.55 These outcomes suggest that, in older patients, an extended inhaled insulin dose can be required to acquire similar diabetes control.

Adverse effects

The negative results of inhaled insulin are summarized in Table 2. There were no negative results uniquely related to a particular insulin method or transport device.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

Hypoglycemia

Euglycemic-focused treatment plans run the risk of making hypoglycemia crises more frequent and severe. 6 In both T1 and T2DM groups, inhaled insulin is linked with comparable frequencies of hypoglycemia to subcutaneous insulin; no rise in episode severity was noted. 30,35,56 The incidence of hypoglycemia episodes was higher in the cohorts receiving inhaled insulin than it was in the cohorts getting oral agents alone (66% to 76% vs 8%) in a research involving participants with T2DM on oral agent therapy alone prior to study admission. 38 Additionally, the inhaled insulin groups had increased incidence of hypoglycemia-related symptoms such tremor, sweating, and headaches. However, there was no increase in the rate of severe hypoglycemic events, which are defined as those requiring outside assistance. 38

Pulmonary Function

Given that many diabetics will require insulin therapy for the rest of their lives, it is important to comprehend how inhaled insulin affects lung function. The potential toxicity of insulin particles on the alveolar-capillary network and the growthpromoting effects of insulin when it binds competitively, albeit at a substantially lower potency, to insulin growth factor-1 receptors in the lung are both under discussion. 22 In T2DM patients taking inhaled insulin for a 12-week period, Rosenstock et al. found no differences in either forced expiratory volume at 1 second (FEV1), total lung capacity, or carbon monoxide diffusion capacity (DLCO). 38 A 2-year follow-up study in T2DM patients who received inhaled insulin as an additional treatment to oral treatments showed that there was a reduction in In T1DM patients, short-term (6-month) studies have shown that DLCO falls by 0.75 to 1.2 mL/min/mm Hg. 34,35 Only a 4-year extension experiment including patients with T1 and T2DM has examined the long-term effects of inhaled insulin on pulmonary function in individuals with T1DM. Annualized changes in FEV1 were 0.057 0.004 L/year and 0.071 0.023 L/year in the insulin-inhaled group and control group, respectively. Annualized changes in DLCO were 0.376 0.067 mL/min/mmHg and 0.673 0.423 mL/min/mmHg. 59 While Exubera® was on the market, it was advised that all patients have FEV1 testing at baseline, after 6 months of therapy, and annually while taking the medication. This is despite the fact that these experiences seem to indicate that inhaled insulin is safe with regard to lung function. For those who have People on inhaled insulin experience mild to severe coughing more frequently. Typically, reports of coughing episodes accompanied insulin inhalation. 23 However, in research reporting this result, both the rate and the strength of this effect diminished over time. 34,35,38 Subjects utilisingTechnosphere® inhaled insulin versus Technosphere® placebo powder did not exhibit any differences in cough rates. 23 Coughing did not significantly contribute to subjects withdrawing from clinical research, either.

Insulin Antibodies

The delivery of insulin whether subcutaneously, intraperitoneally, or by inhalation leads to the formation of circulating insulin immunoglobulins.60–62 High circulating levels of insulin antibodies may disrupt glycemic control by 2 mechanisms. First, the antibodies may bind to the insulin blocking its action with resulting hyperglycemia.63,64 Secondly, the insulin may then be released from the antibody complex, with inappropriate insulin action (discordant with carbohydrate intake) and delayed hypoglycemia.65,66 In rare cases, true insulin allergies may develop.62 These worries have not been raised by the experience with inhaled insulin. After administering and using inhaled insulin, levels of insulin antibodies were assessed in patients with T1DM and T2DM. The median percentage of antibody binding was 22% higher in T1DM patients taking inhaled insulin compared to those receiving CSII treatment. 67 Insulin antibodies were created in T2DM individuals who were using inhaled insulin. Peak antibody levels were attained between 6 and 12 months after being exposed to inhaled insulin, and they were noticeably lower than those seen in T1DM patients. All groups receiving inhaled insulin saw an increase in insulin antibody levels; however, there was no correlation between antibodies and hypo- or hyperglycemia, deterioration of metabolic control, allergic responses, or other alterations. Therefore, while immune reactions are brought on by the delivery of insulin to the pulmonary system, it has not been shown that these reactions gradually reduce the effectiveness of inhaled insulin 68.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

1.13 Quality of Life and Adherence to Therapy

One of the argued advantages of inhaled insulin therapy is that patients will accept it more readily than injections when insulin therapy needs to be increased or when oral therapy is failing to meet glycemic objectives. According to research by Freemantle et al, patients with poorly managed T2DM are more likely to accept the addition of insulin to their treatment plan if inhaled insulin is an option for therapy. 69 Alternately, Bergenstal et al looked explored whether giving people with poorly managed T2DM the option to use AIR® insulin improved their propensity to select any type of insulin therapy. 70 In this study, participants were randomly assigned to counselling on therapeutic alternatives to increase diabetes care that either omitted or included inhaled According to the study, people were not more likely to add insulin to their treatment plan when it was available as inhaled insulin. In addition, whether inhaled or subcutaneous insulin was administered, both groups experienced a similar improvement in HbA1c. 70 Finally, compared to those receiving subcutaneous medication, T1DM patients who received Exubera® reported higher levels of overall happiness and quality of life. 35 In a 12-week randomised controlled trial comparing inhaled and subcutaneous insulin, Rosenstock et al. observed that 85% of patients assigned to inhaled insulin chose to continue taking it, whereas 75% of those assigned to subcutaneous therapy chose to switch to inhaled insulin. Additionally, the benefit of inhaled insulin therapy on psychological outcomes was sustained after a year of treatment. And had a favourable effect on psychological well-being. 42 This is a significant finding because it indicates that inhaled insulin therapy was being adhered to with a high level of success. The glycemic control in these patients was on par with subcutaneous insulin and did not decline throughout the study's extension phase. Phase of the research,42 indicating that inhaled insulin therapy compliance remained high. Adherence refers to a patient's compliance with a doctor's pharmaceutical orders. Adherence rates decrease with increasing daily dosage and are lowest in chronic conditions. 71 Claxton et al demonstrated that less than 50% of patients adhered to a four times per day drug schedule. 72 Diabetes patients sometimes have various medical issues, necessitating polypharmacy with challenging dose regimens. So, any delivery method that increases adherence in the diabetic group would be appreciated. The number of prescriptions filled, the number of vials of insulin used, and the difference in HbA1c after therapy beginning serve as proxy outcomes because it is challenging to measure adherence to subcutaneous insulin therapy via syringe. The AERx® system keeps track of each insulin administration's date, timing, and effectiveness of the inhalation approach. In a group of T2DM patients using the AERx® system, preprandial insulin administration compliance rates reached 95%, and 97% of patients received fewer than 5 insufficient doses over the course of the study's treatment period. 73 Therefore, this inhaled insulin system may be a helpful tool to promote insulin acceptance and enhance glycemic contro.

1.14 Cost of Inhaled Insulin

Since more medication must be taken to obtain equal glycemic control with inhaled insulin compared to subcutaneous insulin, the price of inhaled insulin is much higher. However, the idea that the availability of alternative insulin delivery systems will increase the possibility that people with diabetes will adhere to their treatment regimens has been a significant driving force for the development of inhaled insulin. When inhaled insulin is an option, people with T2DM may be more willing to start using insulin. 69 Improved diabetes outcomes would result from increased adherence to diabetic management and a reduction in micro- and macrovascular complications. Thus, while assessing the economics of inhaled insulin for quality of life and subsequent therapeutic advantages, it is possible to take into account how affordable it is. Exubera® costs and cost-effectiveness in T2DM patients were thoroughly examined by Black et al.74 Exubera® was shown to cost US$1669/year more to add to a regimen that already contained two oral medicines than basal glargine did. The authors found that while quality of life cost savings of US$110 to US$220 per patient might be realised over 20 years of therapy, this was significantly outweighed by the excess cost compared to basal subcutaneous therapy – US$14,000 to US$20,700. This was determined using a model to calculate cost-effectiveness assuming that inhaled insulin would improve glycemic control and quality of life over the lifetime of the patient. Given that glycemic control is not improved by inhaled insulin over subcutaneous treatment, there would need to be more direct

II. CONCLUSION

Regarding the chance that inhaled insulin would be utilised clinically in the future, a number of significant difficulties still need to be resolved. The first is the substantial effect that Exuberaintroduction ®'s and subsequent removal from

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

the market had on the ongoing research and development of rival inhaled insulin devices. The second significant development is the Pfizer research indicating a higher incidence of lung cancer among former smokers who had Exubera® treatment. 49 It is likely that as a result of this information, the FDA will restrict the use of inhaled insulin to those who have never smoked and demand thorough postmarketing studies to address concerns regarding the potential of carcinogenicity. Lastly, as technology has continued to advance, it has become possible to deliver In comparison to subcutaneous insulin, such as insulin pens and pumps, inhaled insulin may not have as much of a market share in the diabetic market. Although the idea of inhaled insulin is intriguing, future advancements in this field will be substantially hampered by the availability of subcutaneous insulin regimens that offer rigorous diabetic management as well as worries about pulmonary function and health. As a result, inhaled insulin represents a novel method of delivering insulin and has the potential to be used to treat both T1DM and T2DM. Clinical studies have generally shown that inhaled insulin does not perform worse than subcutaneous insulin in terms of glycemic management. Additionally, inhaled insulin is a useful adjuvant therapy for people with T2DM who are not well managed on oral medication. The fact that inhaled insulin therapy is highly received by patients and raises overall satisfaction levels is its most apparent advantage over subcutaneous insulin therapy. Therefore, having access to inhaled insulin may result in better diabetes management and a reduced risk of long-term diabetic problems.

REFERENCES

[1]. Centers for Disease Control and Prevention. "National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011." Atlanta, GA: US department of health and human services, centers for disease control and prevention 201, no. 1 (2011): 2568-2569.

[2]. Bakker, W., Eringa, E.C., Sipkema, P. and van Hinsbergh, V.W., 2009. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and tissue research, 335(1), pp.165-189.

[3]. Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D. and Multiple Risk Factor Intervention Trial Research Group, 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes care, 16(2), pp.434-444.

[4]. Krolewski, A.S., Kosinski, E.J., Warram, J.H., Leland, O.S., Busick, E.J., Asmal, A.C., Rand, L.I., Christlieb, A.R., Bradley, R.F. and Kahn, C.R., 1987. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. The American journal of cardiology, 59(8), pp.750-755.

[5]. Laing, S.P., Swerdlow, A.J., Slater, S.D., Burden, A.C., Morris, A., Waugh, N.R., Gatling, W., Bingley, P.J. and Patterson, C.C., 2003. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia, 46(6), pp.760-765.

[6]. Diabetes Control and Complications Trial Research Group, 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England journal of medicine, 329(14), pp.977986.

[7]. UK Prospective Diabetes Study (UKPDS) Group, 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The lancet, 352(9131), pp.837-853.

[8]. Zambanini, A., Newson, R.B., Maisey, M. and Feher, M.D., 1999. Injection related anxiety in insulin-treated diabetes. Diabetes research and clinical practice, 46(3), pp.239246.

[9]. Prentki, M.A.R.C. and Matschinsky, F.M., 1987. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiological reviews, 67(4), pp.1185-1248.

[10]. Porte, D., Sherwin, R.S., Baron, A., Ellenberg, M. and Rifkin, H., 2003. Ellenberg and Rifkin's diabetes mellitus. McGraw-Hill, Health Professions Division.

[11]. Mastrandrea, L.D., 2010. Inhaled insulin: overview of a novel route of insulin administration. Vascular health and risk management, 6, p.47.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

[12]. Logtenberg, S.J., Kleefstra, N., Houweling, S.T., Groenier, K.H., Gans, R.O., van Ballegooie, E. and Bilo, H.J., 2009. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes care, 32(8), pp.1372-1377.

[13]. Laqueur, E. and Grevenstuk, A., 1924. Über die wirkungintratrachealerzuführung von insulin. Klinische Wochenschrift, 3(28), pp.1273-1274.

[14]. Gänsslen, M., 1925. Über inhalation von insulin. KlinischeWochenschrift, 4(2), pp.71-71.

[15]. Patton, J.S. and Byron, P.R., 2007. Inhaling medicines: delivering drugs to the body through the lungs. Nature reviews Drug discovery, 6(1), pp.67-74.

[16]. Usmani, O.S., Biddiscombe, M.F. and Barnes, P.J., 2005. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. American journal of respiratory and critical care medicine, 172(12), pp.1497-1504.

[17]. Katz, I.M., Schroeter, J.D. and Martonen, T.B., 2001. Factors affecting the deposition of aerosolized insulin. Diabetes technology & therapeutics, 3(3), pp.387-397.

[18]. Farr, S.J., McElduff, A., Mather, L.E., Okikawa, J., Ward, M.E., Gonda, I., Licko, V. and Rubsamen, R.M., 2000. Pulmonary insulin administration using the AERx® system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes technology & therapeutics, 2(2), pp.185-197.

[19]. Mastrandrea, L.D., 2010. Inhaled insulin: overview of a novel route of insulin administration. Vascular health and risk management, 6, p.47.

[20]. Schatz, H., 2004. Inhaled insulin and the dream of a needle-free insulin application. Experimental and Clinical Endocrinology & Diabetes, 112(06), pp.285-287.

[21]. Elliott, R.B., Edgar, B.W., Pilcher, C.C., Quested, C. and McMaster, J., 1987. Parenteral absorption of insulin from the lung in diabetic children. Journal of Paediatrics and Child Health, 23(5), pp.293-297.

[22]. Patton, J.S., Bukar, J.G. and Eldon, M.A., 2004. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clinical pharmacokinetics, 43(12), pp.781-801.

[23]. Rosenstock, J., Bergenstal, R., DeFronzo, R.A., Hirsch, I.B., Klonoff, D., Boss, A.H., Kramer, D., Petrucci, R., Yu, W., Levy, B. and 0008 Study Group, 2008. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care, 31(11), pp.2177-2182.

[24]. Rave, K., Heise, T., PFutzner, A.N.D.R.E.A.S. and Boss, A.H., 2007. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes care, 30(9), pp.2307-2308.

[25]. ClincalTrialsgov [homepage on the Internet] A service of the US National Institutes of Health. URL: www.ClinicalTrials.gov/ct2/results?term=inhaled+insulin Accessed September 23, 2009.

[26]. Garg, S.K. and Kelly, W.C., 2009. Insulin Delivery via Lungs—Is It Still Possible?. Diabetes Technology & Therapeutics, 11(S2), pp.S-1.

[27]. Rave, K., Bott, S., Heinemann, L., Sha, S., Becker, R.H., Willavize, S.A. and Heise, T., 2005. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes care, 28(5), pp.1077-1082

[28]. Rave, K., Potocka, E., Boss, A.H., Marino, M., Costello, D. and Chen, R., 2009.Pharmacokinetics and linear exposure of AFRESA™ compared with the subcutaneous injection of regular human insulin. Diabetes, Obesity and Metabolism, 11(7), pp.715-720..

[29]. Brunner, G.A., Balent, B., Ellmerer, M., Schaupp, L., Siebenhofer, A., Jendle, J.H., Okikawa, J. and Pieber, T.R., 2001. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia, 44(3), pp.305-308.

[30]. Cefalu, W.T., Skyler, J.S., Kourides, I.A., Landschulz, W.H., Balagtas, C.C., Cheng, S.L., Gelfand, R.A. and Inhaled Insulin Study Group*, 2001. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Annals of internal medicine, 134(3), pp.203-207.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

[31]. Cefalu, W.T., Skyler, J.S., Kourides, I.A., Landschulz, W.H., Balagtas, C.C., Cheng, S.L., Gelfand, R.A. and Inhaled Insulin Study Group*, 2001. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Annals of internal medicine, 134(3), pp.203-207.

[32]. de la Pena, A., Seger, M., Rave, K., Heinemann, L., Silverman, B. and Muchmore, D.B., 2009. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technology & Therapeutics, 11(S2), pp.S-75.

[33]. Mastrandrea, L.D., 2010. Inhaled insulin: overview of a novel route of insulin administration. Vascular health and risk management, 6, p.47.

[34]. Skyler, J.S., Weinstock, R.S., Raskin, P., Yale, J.F., Barrett, E., Gerich, J.E., Gerstein, H.C. and Inhaled Insulin Phase III Type 1 Diabetes Study Group, 2005. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes care, 28(7), pp.1630-1635.

[35]. Hollander, P.A., Blonde, L., Rowe, R., Mehta, A.E., Milburn, J.L., Hershon, K.S., Chiasson, J.L., Levin, S.R. and Exubera Phase III Study Group, 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes care, 27(10), pp.2356-2362.

[36]. Garg, S.K., Mathieu, C., Rais, N., Gao, H., Tobian, J.A., Gates, J.R., Ferguson, J.A., Webb, D.M. and Berclaz, P.Y., 2009. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: an open-label randomized controlled trial. Diabetes technology & therapeutics, 11(S2), pp.S-5.

[37]. Kapsner, P., Bergenstal, R. and Rendell, M., 2009. Comparative efficacy and safety of technosphere insulin and a rapid-acting analogue both given with glargine in subjects with type 1 diabetes mellitus in a 52-week study. Diabetologia, 52(suppl 1), p.S386.

[38]. Rosenstock, J., Zinman, B., Murphy, L.J., Clement, S.C., Moore, P., Bowering, C.K., Hendler, R., Lan, S.P. and Cefalu, W.T., 2005. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Annals of internal medicine, 143(8), pp.549-558.

[39]. Hollander, P.A., Blonde, L., Rowe, R., Mehta, A.E., Milburn, J.L., Hershon, K.S., Chiasson, J.L., Levin, S.R. and Exubera Phase III Study Group, 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes care, 27(10), pp.2356-2362.

[40]. Hermansen, K., Ronnemaa, T.A.P.A.N.I., Petersen, A.H., Bellaire, S. and Adamson, U., 2004. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care, 27(1), pp.162-167.

[41]. Rosenstock, J., Eliaschewitz, F.G., Heilmann, C.R., Muchmore, D.B., Hayes, R.P. and Belin, R.M., 2009. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technology & Therapeutics, 11(S2), pp.S-63.

[42]. Rosenstock, J., Cappelleri, J.C., Bolinder, B. and Gerber, R.A., 2004. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes care, 27(6), pp.1318-1323.

[43]. Ford, E.S., Mokdad, A.H. and Gregg, E.W., 2004. Trends in cigarette smoking among US adults with diabetes: findings from the Behavioral Risk Factor Surveillance System. Preventive medicine, 39(6), pp.1238-1242.

[44]. Wise, S., Chien, J., Yeo, K. and Richardson, C., 2006. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly Dura inhaled insulin system. Diabetic medicine, 23(5), pp.510-515.

[45]. Himmelmann, A., Jendle, J., Mellén, A., Petersen, A.H., Dahl, U.L. and Wollmer, P., 2003. The impact of smoking on inhaled insulin. Diabetes Care, 26(3), pp.677-682.

[46]. Becker, R.H., Sha, S., Frick, A.D. and Fountaine, R.J., 2006. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care, 29(2), pp.277-282.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

[47]. Targher, G., Alberiche, M., Zenere, M.B., Bonadonna, R.C., Muggeo, M. and Bonora, E., 1997. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 82(11), pp.36193624.

[48]. Fountaine, R., Milton, A., Checchio, T., Wei, G., Stolar, M., Teeter, J., Jaeger, R. and Fryburg, D., 2008. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera®) pharmacokinetics. British journal of clinical pharmacology, 65(6), pp.864-870.

[49]. Kling, J., 2008. Inhaled insulin's last gasp?. Nature biotechnology, 26(5), pp.479-481.

[50]. McElduff, A., Mather, L.E., Kam, P.C. and Clauson, P., 2005. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx® insulin Diabetes Management System. British journal of clinical pharmacology, 59(5), pp.546551.

[51]. Wolzt, M., de la Peña, A., Berclaz, P.Y., Tibaldi, F.S., Gates, J.R. and Muchmore, D.B., 2008. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. Diabetes Care, 31(4), pp.735-740.

[52]. Mannino, D.M., Thorn, D., Swensen, A. and Holguin, F., 2008. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. European Respiratory Journal, 32(4), pp.962-969.

[53]. Rave, K., De La Pena, A., Tibaldi, F.S., Zhang, L., Silverman, B., Hausmann, M., Heinemann, L. and Muchmore, D.B., 2007. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes care, 30(7), pp.1777-1782.

[54]. McGrath, M.W. and Thomson, M.L., 1959. The effect of age, body size and lung volume change on alveolar-capillary permeability and diffusing capacity in man. The Journal of physiology, 146(3), p.572.

[55]. Henry, R.R., Mudaliar, S., Chu, N., Kim, D., Armstrong, D., Davis, T.T., An, B. and Reinhardt, R.R., 2003. Young and elderly type 2 diabetic patients inhaling insulin with the AERx® insulin diabetes management system: A pharmacokinetic and pharmacodynamic comparison. The Journal of Clinical Pharmacology, 43(11), pp.1228-1234.

[56]. Skyler, J.S., Cefalu, W.T., Kourides, I.A., Landschulz, W.H., Balagtas, C.C., Cheng, S.L., Gelfand, R.A. and Inhaled Insulin Phase II Study Group, 2001. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. The Lancet, 357(9253), pp.331-335.

[57]. Barnett, A.H., Lange, P., Dreyer, M., SerdarevicPehar, M. and Exubera® Phase 3 Study Group, 2007. Long term tolerability of inhaled human insulin (Exubera®) in patients with poorly controlled type 2 diabetes. International journal of clinical practice, 61(10), pp.1614-1625.

[58]. Davis, W.A., Knuiman, M., Kendall, P., Grange, V. and Davis, T.M., 2004. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes care, 27(3), pp.752-757.

[59]. Skyler, J.F., 2004, June. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. In Diabetes (Vol. 53, pp. A115-A115). 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC.

[60]. Dahl-Jørgensen, K., Torjesen, P., Hanssen, K.F., Sandvik, L. and Aagenæs, Ø., 1987. Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes, 36(1), pp.1-5.

[61]. Lassmann-Vague, V., Belicar, P., Raccah, D., Vialettes, B., Sodoyez, J.C. and Vague, P., 1995. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps: metabolic consequences. Diabetes Care, 18(4), pp.498-503.

[62]. Schernthaner, G., 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes care, 16(Supplement_3), pp.155-165.

[63]. 199316Suppl 3155–165. [PubMed] [Google Scholar]

[64]. Walford S, Allison SP, Reeves WG. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia. 1982;22(2):106–110.64. Peters, A., Kerner, W., Klose, O., Hefty, R. and Keck, F., 1995. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Diabetic medicine, 12(10), pp.925-930.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
Volume 3, Issue 2, March 2023
Impact Factor: 7.301

[65]. Seewi, O., Jaeger, C., Bretzel, R.G. and Schönau, E., 2008. Insulin binding to antibodies is a risk factor for inexplicable severe hypoglycaemia in children with type-1 diabetes mellitus. Experimental and clinical endocrinology & diabetes, 116(05), pp.293297.

[66]. Kim, M.R., Sheeler, L.R., Mansharamani, N., Haug, M.T., Faiman, C. and Gupta, M.K., 1997. Insulin antibodies and hypoglycemia in diabetic patients. Endocrine, 6(3), pp.285-291.

[67]. Fineberg, S.E., Kawabata, T., Finco-Kent, D., Liu, C. and Krasner, A., 2005. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. The Journal of Clinical Endocrinology & Metabolism, 90(6), pp.3287-3294.

[68]. Wolff, R.K., 1998. Safety of inhaled proteins for therapeutic use. Journal of aerosol medicine, 11(4), pp.197-219.

[69]. Freemantle, N., Blonde, L., Duhot, D., Hompesch, M., Eggertsen, R., Hobbs, F.R., Martinez, L., Ross, S., Bolinder, B. and Stridde, E., 2005. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes care, 28(2), pp.427-428.

[70]. Bergenstal, R.M., Freemantle, N., Leyk, M., Cutler Jr, G.B., Hayes, R.P. and Muchmore, D.B., 2009. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. Diabetes Technology & Therapeutics, 11(S2), pp.S-45.

[71]. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487– 496. [PubMed]

[72]. Claxton, A.J., Cramer, J. and Pierce, C., 2001. A systematic review of the associations between dose regimens and medication compliance. Clinical therapeutics, 23(8), pp.1296-1310.

[73]. Cramer, J.A., Okikawa, J., Bellaire, S. and Clauson, P., 2004. Compliance with inhaled insulin treatment using the AERx® iDMS insulin diabetes management system. Diabetes Technology & Therapeutics, 6(6), pp.800-807.

[74]. Black, C., Cummins, E., Royle, P., Philip, S. and Waugh, N., 2007. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic Review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENTSOUTHAMPTON-, 11(33).